NCT04357106

COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Centro de Hematología y Medicina Interna · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

COVID-19 disease has become a very serious global health problem. Treatments for severe forms are urgently needed to lower mortality. Any procedure that improves these forms should be considered, especially those devoid of serious side effects.There is not enough published information on the use of allogeneic convalescent plasma (ACP) in the treatment of severe forms of COVID-19. The use of ACP can be combined with other treatments and has very few adverse effects. It takes 10-14 days for SARS-CoV2-infected patients to produce virus-neutralizing antibodies: within that time they can develop serious complications and die. Injecting PAC into patients with severe forms of COVID-19 shortens the period of risk while the patient produces the antibodies.

Conditions

• COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	Convalescent plasma	Convalescent plasma obtained by aphaeresis from recovered patients.

Timeline

• Start date: 2020-04-13
• Primary completion: 2020-07-01
• Completion: 2020-08-01
• First posted: 2020-04-22
• Last updated: 2020-04-22

Locations

1 site across 1 country: Mexico